Herb drug interaction: effect of Manix® on pharmacokinetic parameters of pefloxacin in rat model.

Sunday Odunke Nduka, Eleje Okonta, Chika Christiana Abba, Peter Chibueze Ihekwereme, Uchenna Ekwedigwe, Matthew Okonta

Abstract read

In one paragraph

Article in Asian Pacific journal of tropical biomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sunday Odunke NdukaDepartment of Clinical Pharmacy and Pharmacy Management, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.

Eleje OkontaDepartment of Clinical Pharmacy and Pharmacy Management, University of Nigeria, Nsukka, Enugu State, Nigeria.

Chika Christiana AbbaDepartment of Pharmaceutical Chemistry, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.

Peter Chibueze IhekweremeDepartment of Pharmacology and Toxicology, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.

Uchenna EkwedigweDepartment of Clinical Pharmacy and Pharmacy Management, University of Nigeria, Nsukka, Enugu State, Nigeria.

Matthew OkontaDepartment of Clinical Pharmacy and Pharmacy Management, University of Nigeria, Nsukka, Enugu State, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effect of Manix®, the commonly used polyherbal formulation on pefloxacin pharmacokinetic parameters.

methodsMicrobiological assay was employed using clinical isolate of Escherichia coli samples from hospitalized patients.

resultsManix® altered the bioavailability parameters of pefloxacin as thus, maximal concentration (Cmax) of pefloxacin (0.91±0.31) µg/mL occurred at time to reach maximal concentration (tmax) 4.0 h while in the group that received Manix® alongside pefloxacin Cmax was (0.22±0.08) µg/mL at tmax 1.0 h respectively. The area under curve of pefloxacin alone was (7.83±5.14) µg/h/mL while with Manix® was (2.60±0.08) µg/h/mL. There was a significant difference between Cmax, tmax and area under curve between pefloxacin alone and pefloxacin after Manix® pre-treatment (P<0.05).

conclusionsThe concurrent use of Manix® and pefloxacin has been found to compromise the therapeutic effectiveness of pefloxacin which could lead to poor clinical outcomes in patients.

Indexed as

BioavailabilityEscherichia coliManix®Microbiological assayPefloxacin

Identifiers

PMID25183119

DOI10.12980/APJTB.4.2014C400

PMCPMC4025296

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.